Proactive Investors - Run By Investors For Investors

Isodiol’s BSPG subsidiary receives approval from UK regulators to manufacture CBD

Isodiol said the greenlight from the Medicines and Healthcare Products Regulatory Agency means it can now export its CBD around the world
cbd oil and cannabis flower
CBD is a non-psychoactive cannabinoid found in cannabis which has been touted as a possible treatment for things like pain and stress

BSPG Laboratories, a subsidiary of CBD consumer products maker Isodiol International Inc (CSE:ISOL; OTC:ISOLF), has received approval from UK regulators to manufacture cannabidiol (CBD).

Cannabidiol is a non-psychoactive cannabinoid found in cannabis, and research has suggested it could have several medical benefits such as pain and stress relief.

A first in the industry

With the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), BSPG’s natural CBD isolate can now be exported around the world, subject to pharmaceutical regulations.

“This approval validates the consistent quality of our pure, natural CBD isolate and the patented manufacturing processes,” said Isodiol’s Chief Executive Marcos Agramont.

“This event is a first in the industry and now enables Isodiol to focus on the development of CBD based drugs that will address a myriad of conditions that are affecting so many people around the world.”

He added: “With this approval, we will now rapidly advance our pharmaceutical and drug development divisions.”

Isodiol is currently building a state-of-the-art manufacturing facility which is expected to be up-and-running in the first quarter of 2019.

Once it is completed, the company expects to be able to produce around 20,000 kg of CBD each year, which will help it to “serve this newly created demand for CBD drug development, approved pharmaceutical applications, research, clinical studies, and clinical trials”.

Isodiol shares were down 4.7% to C$0.82 on Thursday morning.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full ISOL profile View Profile

Isodiol International Timeline

Related Articles

Sydney Harbour Bridge
January 23 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
November 14 2018
Ascent, viaThirty Eight Hemp Corp, will exploit the hemp market via its strategic relationship with AgTech Scientific
medicinal cannabis concept
January 31 2019
Zelda has released its December quarterly report confirming multiple trials are on track.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use